Abeona Therapeutics

Abeona Therapeutics is a pioneering gene and cell therapy company, listed on Nasdaq under the ticker ABEO. The company operates across manufacturing, delivery, development, and discovery of gene and cell therapies, positioning itself uniquely for success in the rapidly advancing field of genetic medicine. With a fully-operational manufacturing facility, Abeona is producing therapies and vectors for preclinical and clinical studies, while also developing the AIM™ Vector Platform, comprising 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.

Founded in 1989, Abeona Therapeutics specializes in Biotechnology, Health Care, and Manufacturing. The company’s robust and diverse pipeline is led by a gene-corrected cell therapy expected to enter Phase 3 in mid-2019. Additionally, Abeona is pursuing one-time gene therapy candidates across four lysosomal storage diseases, with several preclinical discoveries, including a program in cystic fibrosis using the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.

The company recently secured a $20.00M post-IPO debt investment on 08 January 2024. With its headquarters in the United States, Abeona Therapeutics is poised to make significant strides in the development of innovative genetic medicines.